A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to "modestly" greater improvements in itchiness over placebo, but was associated with adverse events, a randomized ...
STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients ...
Notalgia paresthetica, a neuropathic disorder characterized by recurrent itching in the upper back, is resistant to many treatments. Oral difelikefalin is being studied as a potential therapy. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results